Efficacy and safety of romosozumab among Japanese postmenopausal women with osteoporosis and mild-to-moderate chronic kidney disease

[1] Yoshimura N(2016)Epidemiology of locomotive organ disorders and symptoms: an estimation using the population-based cohorts in japan Clin Rev Bone Miner Metab 14 68-73

[2] Nakamura K(2021)Prevalence, recognition and management of chronic kidney disease in Japan: population-based estimate using a healthcare database with routine health checkup data Clin Kidney J 106 397-409

[3] Takeuchi M(2021)Denosumab safety and efficacy among participants in the FREEDOM extension study with mild to moderate chronic kidney disease J Clin Endocrinol Metab 14 570-576

[4] Shinkawa K(2003)Relationship between age, renal function and bone mineral density in the US population Osteoporos Int 29 2129-2138

[5] Yanagita M(2018)Association of renal function with bone mineral density and fracture risk in the Longitudinal Aging Study Amsterdam Osteoporos Int 8 1367-1376

[6] Kawakami K(2013)Estimated GFR and fracture risk: a population-based study Clin J Am Soc Nephrol 370 412-420

[7] Broadwell A(2014)Romosozumab in postmenopausal women with low bone mineral density N Engl J Med 26 19-26

[8] Chines A(2011)Single-dose, placebo-controlled, randomized study of AMG 785, a sclerostin monoclonal antibody J Bone Miner Res 375 1532-1543

[9] Ebeling PR(2016)Romosozumab treatment in postmenopausal women with osteoporosis N Engl J Med 34 419-428

[10] Franek E(2019)One year of romosozumab followed by two years of denosumab maintains fracture risk reductions: results of the FRAME extension study J Bone Miner Res 14 59-288

[1] Yoshimura N(2016)Epidemiology of locomotive organ disorders and symptoms: an estimation using the population-based cohorts in japan Clin Rev Bone Miner Metab 14 68-73

[2] Nakamura K(2021)Prevalence, recognition and management of chronic kidney disease in Japan: population-based estimate using a healthcare database with routine health checkup data Clin Kidney J 106 397-409

[3] Takeuchi M(2021)Denosumab safety and efficacy among participants in the FREEDOM extension study with mild to moderate chronic kidney disease J Clin Endocrinol Metab 14 570-576

[4] Shinkawa K(2003)Relationship between age, renal function and bone mineral density in the US population Osteoporos Int 29 2129-2138

[5] Yanagita M(2018)Association of renal function with bone mineral density and fracture risk in the Longitudinal Aging Study Amsterdam Osteoporos Int 8 1367-1376

[6] Kawakami K(2013)Estimated GFR and fracture risk: a population-based study Clin J Am Soc Nephrol 370 412-420

[7] Broadwell A(2014)Romosozumab in postmenopausal women with low bone mineral density N Engl J Med 26 19-26

[8] Chines A(2011)Single-dose, placebo-controlled, randomized study of AMG 785, a sclerostin monoclonal antibody J Bone Miner Res 375 1532-1543

[9] Ebeling PR(2016)Romosozumab treatment in postmenopausal women with osteoporosis N Engl J Med 34 419-428

[10] Franek E(2019)One year of romosozumab followed by two years of denosumab maintains fracture risk reductions: results of the FRAME extension study J Bone Miner Res 14 59-288